DK1316801T3 - Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer - Google Patents

Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer

Info

Publication number
DK1316801T3
DK1316801T3 DK02256808T DK02256808T DK1316801T3 DK 1316801 T3 DK1316801 T3 DK 1316801T3 DK 02256808 T DK02256808 T DK 02256808T DK 02256808 T DK02256808 T DK 02256808T DK 1316801 T3 DK1316801 T3 DK 1316801T3
Authority
DK
Denmark
Prior art keywords
detecting
topology
compositions
methods
treating diseases
Prior art date
Application number
DK02256808T
Other languages
English (en)
Inventor
Jennifer M Burns
Zhenhua Miao
Zheng Wei
Maureen C Howard
Brett A Premack
Thomas J Schall
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Application granted granted Critical
Publication of DK1316801T3 publication Critical patent/DK1316801T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
DK02256808T 2001-11-30 2002-09-30 Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer DK1316801T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33810001P 2001-11-30 2001-11-30
US10/245,850 US7442512B2 (en) 2001-11-30 2002-09-16 Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors

Publications (1)

Publication Number Publication Date
DK1316801T3 true DK1316801T3 (da) 2006-03-06

Family

ID=26937511

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02256808T DK1316801T3 (da) 2001-11-30 2002-09-30 Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer

Country Status (10)

Country Link
US (1) US7442512B2 (da)
EP (2) EP1316801B1 (da)
JP (1) JP4485204B2 (da)
KR (1) KR100961237B1 (da)
AT (1) ATE310955T1 (da)
AU (1) AU2002351213B2 (da)
CA (1) CA2468407A1 (da)
DE (1) DE60207514T2 (da)
DK (1) DK1316801T3 (da)
WO (1) WO2003047420A2 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871619B2 (en) * 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
EP1365245A1 (en) * 2002-05-23 2003-11-26 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with chemokine receptor 11 (CCR11)
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
DK1691837T3 (da) * 2003-12-10 2012-10-01 Medarex Inc IP-10-antistoffer og anvendelse heraf
EP1723970A4 (en) * 2004-03-09 2009-08-12 Univ Kyoto MEDICAL COMPOSITION WITH CXCR3 INHIBITOR
CN100357738C (zh) * 2004-03-26 2007-12-26 博奥生物有限公司 一种检测小分子化合物的方法
CA2501422C (en) * 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
US20100143899A1 (en) * 2005-05-17 2010-06-10 University Of Vermont And State Agricultural College Methods and products for diagnosing cancer
CN101243319B (zh) * 2005-06-22 2016-01-06 约翰·霍普金斯大学 卵巢癌的生物标记：ctap3-相关蛋白质
RU2449808C2 (ru) 2006-04-21 2012-05-10 Сентокор, Инк. Антагонисты cxcl13 и их применение для лечения воспалительных заболеваний
GB0614755D0 (en) 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
HUE027165T2 (en) 2006-10-02 2016-08-29 Squibb & Sons Llc Human antibodies that bind to CXCR4 and their uses
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2008134020A1 (en) * 2007-04-26 2008-11-06 University Of Vermont And State Agricultural College Ccl18 and ccl3 methods and compositions for detecting and treating cancer
ES2477271T3 (es) * 2007-08-13 2014-07-16 Baxter International Inc. Modulación por IVIG de quimioquinas para el tratamiento de la esclerosis múltiple, la enfermedad de Alzheimer y la enfermedad de Parkinson
JP2010538275A (ja) * 2007-08-31 2010-12-09 マサチューセッツ インスティテュート オブ テクノロジー 自己免疫疾患の処置
US9212226B2 (en) * 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
CN103347896B (zh) 2010-09-02 2017-06-13 瓦西尼斯公司 抗cxcl13抗体和其使用方法
EP2638068B1 (en) 2010-11-08 2018-12-26 Novartis AG Cxcr2 binding polypeptides
WO2012068540A2 (en) 2010-11-19 2012-05-24 Toshio Imai Neutralizing anti-ccl20 antibodies
JP6181040B2 (ja) 2011-03-28 2017-08-16 アブリンクス エン．ヴェー． 二特異性抗ｃｘｃｒ７免疫グロブリン単一可変ドメイン
KR101359317B1 (ko) * 2011-08-23 2014-02-10 건양대학교산학협력단 Ｄ6 디코이 수용체의 세포 외 도메인 1을 포함하는 항암용 약학 조성물
AU2013225812B2 (en) 2012-03-02 2017-11-30 Vaccinex, Inc. Methods for the treatment of B cell-mediated inflammatory diseases
EP2682187B1 (en) * 2012-07-02 2017-09-13 Molecular Devices, LLC Selection method and apparatus
ES2747836T3 (es) 2012-09-06 2020-03-11 Adelaide Research&Innovation Pty Ltd Métodos y productos para prevenir y/o tratar el cáncer metastásico
WO2014121053A1 (en) 2013-01-31 2014-08-07 Vaccinex, Inc. Methods for increasing immunoglobulin a levels
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
JP6786526B2 (ja) 2015-06-03 2020-11-18 ザ メディカル カレッジ オブ ウィスコンシン インクＴｈｅ Ｍｅｄｉｃａｌ Ｃｏｌｌｅｇｅ Ｏｆ Ｗｉｓｃｏｎｓｉｎ， Ｉｎｃ． 改変されたｃｃｌ２０ロックド二量体ポリペプチド
WO2016207124A1 (en) 2015-06-25 2016-12-29 F. Hoffmann-La Roche Ag Cell based assay for determining antibody or ligand binding and function
WO2018056461A1 (ja) 2016-09-26 2018-03-29 学校法人 聖マリアンナ医科大学 卵子、受精卵又は胚の質改善剤
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
CN107312092B (zh) * 2017-05-04 2020-12-11 华南农业大学 一种斜带石斑鱼ccr12的多克隆抗体制备方法及其应用
CN113684238A (zh) * 2021-08-09 2021-11-23 广州医科大学附属第一医院（广州呼吸中心） Cxc趋化因子受体3作为咳嗽药物靶点的用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4927838A (en) 1987-07-10 1990-05-22 Hoffman-La Roche Inc. Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors
US6537764B1 (en) 1995-01-19 2003-03-25 Children's Medical Center Corporation Method of identifying inhibitors of C—C chemokine receptor 3
SE9600820D0 (sv) 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
WO1998011218A1 (en) 1996-09-10 1998-03-19 Theodor-Kocher Institute Cxcr3 chemokine receptor, antibodies, nucleic acids, and methods of use
US6140064A (en) 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
US5876946A (en) 1997-06-03 1999-03-02 Pharmacopeia, Inc. High-throughput assay
EP0897980A3 (en) 1997-08-20 2002-04-17 Smithkline Beecham Corporation CXCR4B: A human splice variant of CXCR4 chemokine receptor
US6306653B1 (en) 1998-01-20 2001-10-23 Codon Diagnostics, Llc Detection and treatment of breast disease
JP4786793B2 (ja) 1998-03-30 2011-10-05 ノースウエスト バイオセラピューティクス，インコーポレイティド 腫瘍形成におけるｃｘｃｒ−４遺伝子の役割に基く治療的および診断的応用
US6287765B1 (en) 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
US6449054B1 (en) * 1998-08-01 2002-09-10 Canon Kabushiki Kaisha Dynamic assignment of group addresses for controlling parallel peripheral devices
US6329510B1 (en) 1999-01-29 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-CCR1 antibodies and methods of use therefor
US6329159B1 (en) 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
US6365356B1 (en) 1999-03-17 2002-04-02 Cornell Research Foundation, Inc. Receptors that regulate cell signaling relating to chemokines
EP1169348B1 (en) * 1999-04-08 2016-02-24 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
US20020061599A1 (en) 1999-12-30 2002-05-23 Elling Christian E. Method of identifying ligands of biological target molecules
KR20030032916A (ko) 2000-02-09 2003-04-26 휴먼 게놈 사이언시즈, 인크. Ｃｃｒ5에 대한 항체
US20020064770A1 (en) 2000-03-21 2002-05-30 Nestor John J. Binding compounds and methods for identifying binding compounds
WO2002000728A2 (en) 2000-06-26 2002-01-03 Gpc Biotech Inc. Methods and compositions for isolating biologically active antibodies

Also Published As

Publication number Publication date
JP2005527189A (ja) 2005-09-15
AU2002351213B2 (en) 2008-01-03
WO2003047420A3 (en) 2004-02-26
EP1316801B1 (en) 2005-11-23
DE60207514T2 (de) 2006-08-10
JP4485204B2 (ja) 2010-06-16
DE60207514D1 (de) 2005-12-29
AU2002351213A1 (en) 2003-06-17
EP1461061A4 (en) 2005-08-31
EP1316801A1 (en) 2003-06-04
US7442512B2 (en) 2008-10-28
ATE310955T1 (de) 2005-12-15
KR20040099258A (ko) 2004-11-26
CA2468407A1 (en) 2003-06-12
AU2002351213B8 (en) 2003-06-17
EP1461061A2 (en) 2004-09-29
WO2003047420A2 (en) 2003-06-12
US20030124628A1 (en) 2003-07-03
KR100961237B1 (ko) 2010-06-03

Similar Documents

Publication Publication Date Title
DK1316801T3 (da) Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
EA200702619A1 (ru) Антагонисты мускариновых ацетилхолиновых рецепторов
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
MA29528B1 (fr) Agents de fixation
ATE554769T1 (de) Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon
BRPI0413922A (pt) xantinas de 8-heteroarila substituìda
TR200300322T2 (tr) Kemokin alıcısını bağlayan heterosiklik bileşikler
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
ATE515702T1 (de) Verfahren, mixturen, kits und zusammensetzungen bezüglich der analytbestimmung
ATE424560T1 (de) Marker für neuromyelitis optica
DE602005010109D1 (de) 1,1a,5,5a-tetrahydro-3-thia-cyclopropaäaüpentaleneptor-agonisten
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
NO20060775L (no) Muskarine acetylkolinreseptorantagonister
IL174195A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
WO2004108887A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
DE60323496D1 (de) Reinigungsmittel für harte oberflächen
HRP20041224A2 (en) Cck-1 receptor modulators
BR0015872A (pt) Agentes antitrombóticos
WO2006104761A3 (en) Unique sequence hybridization probes (usp)
TR200100240T2 (tr) Anksiyete bozukluklarının tedavisi
DK1613772T3 (da) Fremgangsmåde til bestemmelse af tilstanden af jord